An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
Trial Status: complete
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics,
Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736
in Adult Participants with Select Advanced Solid Tumors
Inclusion Criteria
Adult participants; age ≥ 18
Written and signed informed consent must be obtained
Have histologic or cytologic documentation of solid tumor including EGFRm NSCLC
Participants must have at least 1 lesion that is measurable using RECIST guidelines
Participants must consent to provide archived tumor specimens or tumor biopsies for correlative biomarker studies.
Eastern Cooperative Oncology Group performance score of 0 or 1
Adequate organ function
Exclusion Criteria
Prior treatment with tumor necrosis factor receptor superfamily agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR). One cohort also excludes anti CTLA-4, PD-L1, and anti PD-L1.
Participants who have received prior therapy with regimens containing CTLA-4, PD-L1, or PD-1 antagonists may be permitted to enroll under certain conditions
Cardiac or peripheral vascular disease meeting any of the following criteria:
Past history of myocardial infarction in the prior 12 months
Past history of stroke or transient ischemic attack requiring medical therapy
Congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification
Grade 3 or greater edema (eg, peripheral, pulmonary)
History of Grade 3 or greater thromboembolic events in the prior 12 months
Participants with active tuberculosis are ineligible. In settings where there is clinical or radiographic evidence of tuberculosis, active disease must be ruled out
Active or prior documented autoimmune or inflammatory disorders
Untreated central nervous system (CNS) metastatic disease
Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
Other invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, active peptic ulcer disease or gastritis, uncontrolled hypertension, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirement
Additional locations may be listed on ClinicalTrials.gov for NCT02503774.
